Published in Invest Ophthalmol Vis Sci on January 01, 2004
Beta2 integrins control the severity of murine Lyme carditis. Infect Immun (2005) 0.97
Cytokine/chemokine profiles contribute to understanding the pathogenesis and diagnosis of primary Sjögren's syndrome. Clin Exp Immunol (2012) 0.95
Pharmacological cholinergic blockade stimulates inflammatory cytokine production and lymphocytic infiltration in the mouse lacrimal gland. Invest Ophthalmol Vis Sci (2011) 0.95
Aggravated Lyme carditis in CD11a-/- and CD11c-/- mice. Infect Immun (2005) 0.92
Flotillin-1 stabilizes caveolin-1 in intestinal epithelial cells. Biochem Biophys Res Commun (2008) 0.92
Th2 cytokine genotypes are associated with a milder form of primary Sjogren's syndrome. Ann Rheum Dis (2005) 0.86
Autoimmune Th2-mediated dacryoadenitis in MRL/MpJ mice becomes Th1-mediated in IL-4 deficient MRL/MpJ mice. Invest Ophthalmol Vis Sci (2007) 0.84
Salivary chemokine levels in patients with primary Sjogren's syndrome. Rheumatology (Oxford) (2010) 0.81
Destruction of salivary and lacrimal glands by Th1-polarized reaction in a model of secondary Sjögren's syndrome in lupus-prone female NZB × NZWF(1) mice. Inflammation (2012) 0.76
Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ (2009) 2.23
Evaluation of patients with scleritis for systemic disease. Ophthalmology (2004) 2.22
Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology (2011) 2.00
Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol (2008) 1.87
The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol (2010) 1.83
Chlamydiae as etiologic agents in chronic undifferentiated spondylarthritis. Arthritis Rheum (2009) 1.77
Cyclosporine for ocular inflammatory diseases. Ophthalmology (2010) 1.75
Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss. Am J Ophthalmol (2007) 1.66
Adverse effects of smoking on patients with ocular inflammation. Br J Ophthalmol (2010) 1.61
Methotrexate for ocular inflammatory diseases. Ophthalmology (2009) 1.58
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol (2008) 1.56
Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology (2010) 1.54
Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology (2008) 1.46
Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology (2005) 1.46
Multifocal choroiditis with panuveitis incidence of ocular complications and of loss of visual acuity. Ophthalmology (2006) 1.45
Azathioprine for ocular inflammatory diseases. Am J Ophthalmol (2009) 1.44
Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol (2006) 1.43
Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol (2009) 1.41
Punctate inner choroidopathy: a survey analysis of 77 persons. Ophthalmology (2007) 1.36
Improving the reporting of clinical case series. Am J Ophthalmol (2005) 1.36
Reactive arthritis: clinical aspects and medical management. Rheum Dis Clin North Am (2009) 1.35
Multifocal choroiditis with panuveitis and punctate inner choroidopathy: comparison of clinical characteristics at presentation. Retina (2007) 1.34
Sympathetic ophthalmia: incidence of ocular complications and vision loss in the sympathizing eye. Am J Ophthalmol (2009) 1.33
Birdshot retinochoroidopathy: ocular complications and visual impairment. Am J Ophthalmol (2005) 1.31
Differential expression of three Chlamydia trachomatis hsp60-encoding genes in active vs. persistent infections. Microb Pathog (2004) 1.27
Transcriptome profiling of Saccharomyces cerevisiae during a transition from fermentative to glycerol-based respiratory growth reveals extensive metabolic and structural remodeling. Mol Genet Genomics (2006) 1.26
Visual loss in patients with cytomegalovirus retinitis and acquired immunodeficiency syndrome before widespread availability of highly active antiretroviral therapy. Arch Ophthalmol (2003) 1.24
Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol (2008) 1.23
Chlamydophila pneumoniae and the etiology of late-onset Alzheimer's disease. J Alzheimers Dis (2008) 1.21
Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis. Ophthalmology (2006) 1.20
Protective immunity to cytomegalovirus (CMV) retinitis in AIDS is associated with CMV-specific T cells that express interferon- gamma and interleukin-2 and have a CD8+ cell early maturational phenotype. J Infect Dis (2006) 1.19
Chlamydia trachomatis genes whose products are related to energy metabolism are expressed differentially in active vs. persistent infection. Microbes Infect (2002) 1.19
Risk of vision loss in patients with cytomegalovirus retinitis and the acquired immunodeficiency syndrome. Arch Ophthalmol (2003) 1.18
Detection of nucleotide variability in rpoB in both rifampin-sensitive and rifampin-resistant strains of Chlamydia trachomatis. Antimicrob Agents Chemother (2003) 1.17
Cyclophosphamide for ocular inflammatory diseases. Ophthalmology (2009) 1.14
Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy. Ophthalmology (2008) 1.14
Incidence of and risk factors for visual acuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Ophthalmology (2006) 1.13
Identifying a clinically meaningful threshold for change in uveitic macular edema evaluated by optical coherence tomography. Am J Ophthalmol (2011) 1.12
Mucous membrane pemphigoid and pseudopemphigoid. Ophthalmology (2004) 1.11
Vogt-Koyanagi-Harada disease: clinical outcomes. Am J Ophthalmol (2005) 1.11
Retroviral Foxp3 gene transfer ameliorates liver granuloma pathology in Schistosoma mansoni infected mice. Immunology (2005) 1.11
Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis (2003) 1.10
Dendrimer-enabled DNA delivery and transformation of Chlamydia pneumoniae. Nanomedicine (2013) 1.09
Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency syndrome. Clin Infect Dis (2003) 1.09
Lichen planus and cicatrizing conjunctivitis: characterization of five cases. Am J Ophthalmol (2003) 1.09
Mortality in hepatitis C virus-infected patients with a diagnosis of AIDS in the era of combination antiretroviral therapy. Clin Infect Dis (2012) 1.08
Incidence of cystoid macular edema after cataract surgery in patients with and without uveitis using optical coherence tomography. Am J Ophthalmol (2009) 1.08
Loss of visual field among patients with birdshot chorioretinopathy. Am J Ophthalmol (2007) 1.08
Persistent Chlamydiae and chronic arthritis. Arthritis Res (2001) 1.05
Chlamydophila (Chlamydia) pneumoniae in the Alzheimer's brain. FEMS Immunol Med Microbiol (2006) 1.03
Smoking as a risk factor for cystoid macular edema complicating intermediate uveitis. Am J Ophthalmol (2008) 1.03
The impact of macular edema on visual function in intermediate, posterior, and panuveitis. Ocul Immunol Inflamm (2012) 1.03
Vascular endothelial growth factor inhibition in uveitis: a systematic review. Br J Ophthalmol (2010) 1.03
Risk of hypotony in noninfectious uveitis. Ophthalmology (2012) 1.03
Protective immunity to chlamydial genital infection: evidence from animal studies. J Infect Dis (2010) 1.03
Risk of choroidal neovascularization among the uveitides. Am J Ophthalmol (2013) 1.02
Cytokine and chemokine mRNA produced in synovial tissue chronically infected with Chlamydia trachomatis and C. pneumoniae. J Rheumatol (2002) 1.02
Hypotony in patients with uveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial. Ocul Immunol Inflamm (2012) 1.02
Soluble egg antigens from Schistosoma mansoni induce angiogenesis-related processes by up-regulating vascular endothelial growth factor in human endothelial cells. J Infect Dis (2002) 1.01
Retinal vascular occlusion in patients infected with human immunodeficiency virus. Retina (2005) 1.01
Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Herpes (2007) 1.00
HLA typing in uveitis: use and misuse. Am J Ophthalmol (2010) 1.00
Hypopyon in patients with uveitis. Ophthalmology (2009) 0.99
A method of reporting macular edema after cataract surgery using optical coherence tomography. Retina (2008) 0.99
Dendrimer-enabled modulation of gene expression in Chlamydia trachomatis. Mol Pharm (2012) 0.99
Causes of visual acuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Ophthalmology (2006) 0.99
Safety of intravitreal ketorolac and diclofenac: an electroretinographic and histopathologic study. Retina (2008) 0.98
Challenges in the design and implementation of the Multicenter Uveitis Steroid Treatment (MUST) Trial--lessons for comparative effectiveness trials. Clin Trials (2011) 0.97
Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology (2012) 0.97
Clinical characteristics and outcomes of cytomegalovirus retinitis in persons without human immunodeficiency virus infection. Am J Ophthalmol (2004) 0.97
Association between abnormal contrast sensitivity and mortality among people with acquired immunodeficiency syndrome. Am J Ophthalmol (2010) 0.97
Effect of cytomegalovirus retinitis on the risk of visual acuity loss among patients with AIDS. Ophthalmology (2006) 0.96
Ocular disease in patients with ANCA-positive vasculitis. J Ocul Biol Dis Infor (2009) 0.95
Expression of matrix metalloproteinases and their inhibitors during the resorption of schistosome egg-induced fibrosis in praziquantel-treated mice. Immunology (2004) 0.94
Molecular biology of infectious agents in chronic arthritis. Rheum Dis Clin North Am (2009) 0.93
Change over time in incidence of ganciclovir resistance in patients with cytomegalovirus retinitis. Clin Infect Dis (2007) 0.93
Incidence of cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol (2012) 0.93
Infectious agents and multiple sclerosis--are Chlamydia pneumoniae and human herpes virus 6 involved? J Neuroimmunol (2003) 0.93
New insights into Chlamydia and arthritis. Promise of a cure? Ann Rheum Dis (2013) 0.93
AIDS and ophthalmology, 2008. Arch Ophthalmol (2008) 0.92
Dendrimer-enabled transformation of Chlamydia trachomatis. Microb Pathog (2013) 0.91
The load of Chlamydia pneumoniae in the Alzheimer's brain varies with APOE genotype. Microb Pathog (2005) 0.91
Rsf1p, a protein required for respiratory growth of Saccharomyces cerevisiae. Curr Genet (2003) 0.90
The evolving story of Chlamydia-induced reactive arthritis. Curr Opin Rheumatol (2010) 0.90
The molecular genetic basis of mitochondrial malfunction in bladder tissue following outlet obstruction. J Urol (2004) 0.90